Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population

被引:0
作者
Mes, Jurriaan J. [1 ]
van den Belt, Maartje [1 ]
van der Haar, Sandra [1 ]
Oosterink, Els [1 ]
Luijendijk, Teus [2 ]
Manusama, Koen [3 ]
van Dam, Lotte [3 ]
de Bie, Tessa [3 ]
Witkamp, Renger [3 ]
Esser, Diederik [1 ]
机构
[1] Wageningen Food & Biobased Res, Food Hlth & Consumer Res, Bornse Weilanden 9, NL-6708 WG Wageningen, Netherlands
[2] Stichting Control Food & Flowers, Distributieweg 1, NL-2645 EG Delfgauw, Netherlands
[3] Wageningen Univ & Res, Div Human Nutr & Hlth, Stippeneng 4, NL-6708 WE Wageningen, Netherlands
关键词
Momordica charantia; Bitter gourd; Prediabetic; Type 2 diabetes mellitus; Fasting plasma glucose; Clinical trial; Safety; TYPE-2; METFORMIN; REMISSION;
D O I
10.1016/j.jep.2025.119756
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Bitter gourd (Momordica charantia L.) is known for its ability to reduce parameters of diabetes, but its effects on prediabetic subjects have been scarcely studied. Aim of the study: To assess the efficacy of Momordica charantia supplementation in a prediabetic population on markers of glucose homeostasis. Methods: Two randomized controlled studies were conducted to assess the effect of bitter gourd supplementation in a prediabetic population. Study 1 was a 4-week cross-over intervention trial (n = 30), with freeze-dried bitter gourd (BG) fruit juice (2.4 g/day) or a cucumber-based control product (CC). Study 2 was a parallel trial (n = 38) lasting 12 weeks, with freeze-dried whole fruits (3.6 g/day) or a cucumber-based matched control supplement. Effects on fasting plasma glucose (FPG), insulin, HbA1c, fructosamine, postprandial glucose after an oral glucose tolerance test, and several safety biomarkers were also analyzed in both trials before and after the interventions. Results: In Study 1, no significant differences were found between the bitter gourd and placebo interventions. However, a reduction in FPG in subjects with higher baseline values were found following bitter gourd supplementation, which was not observed in the control group. However, in Study 2, we observed significant reductions of FPG (p = 0.014), fasting insulin (p = 0.007), and HOMA-IR (p = 0.003) after a 12-week intervention with the bitter gourd supplement. In addition, between treatment analysis resulted in significant effects on FPG levels (p = 0.026) and HOMA-IR (p = 0.045) with no significant effects on other biomarkers related to glucose metabolism. On average, bitter gourd intervention reduced FPG by similar to 0.05 mmol/L per week, whereas FPG remained unchanged following placebo. In both studies, there were no indications of health risks or side effects from consumption of the supplements. Conclusion: Results suggest that supplementation with bitter gourd fruit can have positive effects on fasting plasma glucose and insulin among prediabetic subjects when provided over an extended period of at least 12 weeks.
引用
收藏
页数:9
相关论文
共 33 条
[11]  
Koslover J., 2022, Br. J. Clin. Pharmacol., V27
[12]   Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania [J].
Krawinkel, Michael B. ;
Ludwig, Christine ;
Swai, Mark E. ;
Yang, Ray-yu ;
Chun, Kwok Pan ;
Habicht, Sandra D. .
JOURNAL OF ETHNOPHARMACOLOGY, 2018, 216 :1-7
[13]   The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials [J].
Laczko-Zold, Eszter ;
Csupor-Loffler, Boglarka ;
Kolcsar, Edina-Blanka ;
Ferenci, Tamas ;
Nan, Monica ;
Toth, Barbara ;
Csupor, Dezso .
FRONTIERS IN NUTRITION, 2024, 10
[14]  
Liao PY, 2022, FOOD FUNCT, V13, P1822, DOI [10.1039/d1fo02788c, 10.1039/D1FO02788C]
[15]  
Liu J, 2010, OLIVES AND OLIVE OIL IN HEALTH AND DISEASE PREVENTION, P1423
[16]   A personalized multi-interventional approach focusing on customized nutrition, progressive fitness, and lifestyle modification resulted in the reduction of HbA1c, fasting blood sugar and weight in type 2 diabetes: a retrospective study [J].
Mehra, Chhavi Goyal ;
Raymond, Annie Mattilda ;
Prabhu, Rekha .
BMC ENDOCRINE DISORDERS, 2022, 22 (01)
[17]   Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials [J].
Nabrdalik, Katarzyna ;
Skonieczna-Zydecka, Karolina ;
Irlik, Krzysztof ;
Hendel, Mirela ;
Kwiendacz, Hanna ;
Loniewski, Igor ;
Januszkiewicz, Kornelia ;
Gumprecht, Janusz ;
Lip, Gregory Y. H. .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[18]   Regulation of Glucose Homeostasis by GLP-1 [J].
Nadkarni, Prashant ;
Chepurny, Oleg G. ;
Holz, George G. .
GLUCOSE HOMEOSTATIS AND THE PATHOGENESIS OF DIABETES MELLITUS, 2014, 121 :23-65
[19]  
Nasri H, 2014, J RES MED SCI, V19, P658
[20]  
Noya Leal F.P., 2021, ECRO XXXI: Celebrating the 50th Anniversary of ECRO-Cascais 8-9